Minerva Neurosciences | NERV - Loan Capital


Minerva Neurosciences reported $0 in Loan Capital for its fiscal quarter ending in September of 2024.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Adma Biologics USD 70.08M 3.32M Sep/2025
ALKERMES USD 285.82M 639K Sep/2024
Alterity Therapeutics Limited AUD 103.21K 73.88K Jun/2023
AstraZeneca USD 26.14B 19.58B Dec/2025
BioCryst Pharmaceuticals USD 194.37M 48.43M Sep/2025
Bristol-Myers Squibb USD 42.85B 1.62B Dec/2025
Cipla INR 2.98B 454.6M Sep/2025
Clal Biotechnology ILS 25.96M 18.48M Dec/2023
Compugen USD 0 0 Dec/2024
CSL USD 10.42B 273M Dec/2025
Eli Lilly USD 40.87B 5.6M Dec/2025
Esperion Therapeutics USD 262.48M 235.95M Jun/2024
GlaxoSmithKline GBP 14.71B 186M Dec/2025
Grifols EUR 10.67B 564.4M Sep/2025
Halozyme Therapeutics USD 2.14B 1.34B Dec/2025
Ionis Pharmaceuticals USD 1.9B 1.87B Dec/2025
J&J USD 39.44B 30M Dec/2025
Merck USD 39.97B 6B Sep/2025
Minerva Neurosciences USD 0 86.58M Sep/2024
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 24.24B 174M Sep/2025
Novavax USD 223.63M 187K Sep/2024
Pfizer USD 57.41B 93M Sep/2025
Roche Holding CHF 27.43B 966M Dec/2025
Sanofi EUR 15.72B 2.45B Dec/2025
Takeda JPY 4.27T 81.29B Dec/2025
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024